Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cinryze: Phase III data

Data from the 24-patient prophylactic portion of the double-blind U.S. Phase III CHANGE trial showed that Cinryze met the primary endpoint of a significant reduction in HAE

Read the full 274 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE